News | September 03, 2014

Research at Jobst Vascular Institute Examines Safety and Effectiveness of Stents for Veins


September 3, 2014 — Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. For years, stents have been used to treat narrowed or blocked arteries; however none are specifically designed for use in veins. The Cook Medical VIVO clinical research study aims to determine the safety and effectiveness of the Zilver vena venous self-expanding stent in the treatment of vein obstructions. Jobst Vascular Institute is the second center in the country to enroll a patient in the VIVO clinical research study.

“Veins differ greatly from arteries and require a different approach when treating blockages,” said Anthony Comerota, M.D., one of two global principal investigators in the VIVO clinical research study. “While arteries are muscular and under high pressure as they deliver blood throughout the body, veins are low-pressure vessels that return blood to the heart. When obstructed, they require stent characteristics different from those required by an artery.”

Vein obstruction or iliofemoral venous outflow obstruction is a blockage or narrowing of the major veins draining blood from the leg. It causes leg pain, throbbing, swelling and skin discoloration in the legs. It may also be associated with deep vein thrombosis, a blood clot in the leg. Patients are currently treated only with compression stockings or by elevating the leg. Some patients may be taking blood thinners.

“This is an important trial, which may expand the options for treating diseased veins,” said Comerota.

The Zilver vena venous self-expanding stent is an investigational device that is not approved for sale in the United States.

For more information: www.promedica.org/jobst, www.cookmedical.com


Related Content

News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
Subscribe Now